Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The product is expected to be launched by Q4 FY23.
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
Prime Minister Narendra Modi attended an event marking the 100th robotic-assisted surgical system installation at U. N. Mehta Institute of Cardiology, Ahmedabad.
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Ties up with Denmark’s Vestfrost Solutions, to cater to the unique needs of the Indian market
Subscribe To Our Newsletter & Stay Updated
